<DOC>
	<DOCNO>NCT01726400</DOCNO>
	<brief_summary>The standard treatment chronic hepatitis C infection pegylated interferon alpha combine ribavirin . Anaemia common complication occur 30 % subject . Unfortunately , side effect interferon ribavirin therapy require dose reduction , reduce likelihood sustain viral response . Recent data show interferon alpha may increase hepcidin ( key iron regulator ) production , result impaired iron availability production red blood cell . In study , evaluate hepcidin level 30 patient Hepatitis C treat interferon contain regime . If hepcidin play role interferon-induced anaemia , cheap readily available oral hepcidin inhibitor could trialled potentially reduce impact interferon alpha induce anaemia .</brief_summary>
	<brief_title>In Hepatitis C Patients Treated With Interferon Ribavirin , Does Hepcidin Contribute Treatment Induced Anaemia</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Hepcidins</mesh_term>
	<criteria>Any patient hepatitis C eligible treatment pegylated interferon alpha contain regime . le 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Hepcidin</keyword>
	<keyword>Iron metabolism</keyword>
</DOC>